EE370 Assessing the Impact of Crossover Adjustment on the Cost-Effectiveness (CE) of Nivolumab Versus Everolimus in Pre-Treated Advanced Renal Cell Carcinoma (ARCC) in the United States (US)
- Resource Type
- Abstract
- Source
- In
Value in Health July 2022 25(7) Supplement:S407-S408 - Subject
- Language
- ISSN
- 1098-3015